Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases

Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases

Introduction Patients with metastatic disease are considered incurable. We previously showed that nabpaclitaxel (nanoparticle albumin-embedded paclitaxel) combined with anti-vascular endothelial growth factor A (VEGF-A) antibody, bevacizumab, eradicates orthotopic small-sized breast tumors and meta...

Full description

Bibliographic Details
Main Authors:	Lisa D. Volk, Michael J. Flister, Deena Chihade, Neil Desai, Vuong Trieu, Sophia Ran
Format:	Article
Language:	English
Published:	Elsevier 2011-04-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S147655861180014X

Similar Items

Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Anti–Vascular Endothelial Growth Factor A Therapy
by: Lisa D. Volk, et al.
Published: (2008-06-01)

The Combination of Nab-Paclitaxel and Bevacizumab Therapy Synergistically Improves Tumor Response in Xenograft Breast Cancer Models
by: Volk, Lisa Danielle
Published: (2008)

nab-Paclitaxel for the treatment of pancreatic cancer
by: Kim G
Published: (2017-03-01)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports
by: Tomoyuki Araya, et al.
Published: (2020-12-01)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
by: Kunihiko Funaishi, et al.
Published: (2017-06-01)

Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
by: Xi Guo, MD, et al.
Published: (2020-03-01)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
by: Al-Hajeili M, et al.
Published: (2014-02-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer
by: Alberto Montero, et al.
Published: (2012-12-01)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
by: Prakash Vishnu, et al.
Published: (2011-04-01)

The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer
by: M A Frolova
Published: (2016-09-01)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, nab-Paclitaxel)
by: Vera eHirsh, et al.
Published: (2014-07-01)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
by: Iwase H, et al.
Published: (2011-07-01)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
by: De Luca R, et al.
Published: (2018-06-01)

Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer
by: Amol Patel, et al.
Published: (2020-01-01)

The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids
by: Xiao X, et al.
Published: (2020-06-01)

Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
by: Frontiers in Oncology Editorial Office
Published: (2014-10-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
by: Go Makimoto, et al.
Published: (2014-01-01)

nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
by: Soliman HH
Published: (2016-12-01)

NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER
by: Jasgit C. Sachdev, et al.
Published: (2016-05-01)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
by: Lazzaro C, et al.
Published: (2013-04-01)

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases
by: Ricciardi GRR, et al.
Published: (2015-02-01)

The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
by: Takashi Higuchi, et al.
Published: (2019-03-01)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
by: Lukas M. Braun, et al.
Published: (2020-05-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
by: Katsurada N, et al.
Published: (2020-02-01)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
by: Anne Steins, et al.
Published: (2017-01-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01)

Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
by: E. I. Borisova, et al.
Published: (2018-11-01)

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
by: Garry Ceccon, et al.
Published: (2020-01-01)

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
by: Hakon Blomstrand, et al.
Published: (2019-01-01)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
by: Thomas M, et al.
Published: (2017-10-01)

Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life
by: De Luca R, et al.
Published: (2019-02-01)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
by: Sun S, et al.
Published: (2014-03-01)

Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer
by: Vineet Talwar, et al.
Published: (2020-01-01)

Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma
by: T. Y. S. Le Large, et al.
Published: (2021-03-01)

Differences in Fatty Acid Oxidation between Nab-Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics
by: Jhih-Wei Huang, et al.
Published: (2021-02-01)

Subconjunctival bevacizumab and argon laser photocoagulation for preexisting neovascularization following deep lamellar anterior keratoplasty
by: Meena Lakshmipathy, et al.
Published: (2019-01-01)

Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study
by: I. A. Pokataev, et al.
Published: (2019-12-01)

A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
by: Haili Lu, et al.
Published: (2021-07-01)